Telix Pharmaceuticals Limited - Capital Markets Day - TELIX PHARMACEUTICALS LTD

Financial Performance:

• Revenue guidance maintained at the top end of the previously stated range, targeting approximately $1 billion USD for the current year.
• The precision medicine business segment is projected to exceed 25% year-over-year growth, driven by a multi-product strategy.
• Gross margins for the precision medicine business have improved to 65%, supported by supply chain optimization and vertical integration.
• The company anticipates a shift toward an earnings growth story by 2028, moving from a revenue-focused growth phase.
• ITM11 acquisition adds a separate revenue stream (<del>$300M annual run-rate) and is expected to deliver **</del>$50 million in synergies** within two years; ITM is forecast to grow at an 18% CAGR over the next five years.
• Operating leverage is expected to increase significantly as the commercial team and isotope supply chain costs are amortized across a growing portfolio of approved products.
• Capital allocation is disciplined, funded largely by operations with minimal reliance on external capital dilution.

Guidance and Future Outlook:

• 2027 is now positioned as the key commercial milestone year, previously planned for 2028, driven by the integration of ITM11 and the acceleration of the therapeutic pipeline.
• The company expects to have six FDA-approved products by this time next year (up from three currently), including PixClara, Gazellik, Zirconix (anticipated 2027), and new therapeutics.
• 2028 is targeted for the transition to a sustained earnings growth trajectory, attracting a broader investor base.
• Future revenue trajectory aims for $1.5 billion USD ($2 billion AUD) by next year and significant expansion beyond 2030 as the pipeline matures.
• The strategy emphasizes a "first in human" to commercialization speed advantage, with lead times for product launches decreasing from four months (Eleusix) to two weeks (PixClara) due to integrated supply chains.

Business Segments and Product Lines:

• Urologic Oncology (Prostate): Core focus with three late-stage programs:
  • TLX-591 (Radio-Antibody Drug Conjugate): Phase 3 "Prostac Global" trial ongoing; targets metastatic castration-resistant disease with a two-dose, two-week schedule compatible with other therapies.
  • TLX-597 (Small Molecule): Next-generation Lutetium-177 agent; Phase 3 "Optimal PSMA" trial investigating dose intensification (3 doses in 2 weeks) vs. standard dosing; Phase 3 "Optimal E" in early metastatic hormone-sensitive disease.
  • Bypass Study: Investigating PSMA PET imaging for pre-biopsy diagnosis in prostate cancer, aiming to triple the addressable patient volume by shifting imaging earlier in the diagnostic pathway.
• Neuro-Oncology (Brain Cancer):
  • PixClara (Floretetyltyrosine): FDA-approved for PET imaging of glioma; expected to see widespread adoption for distinguishing tumor recurrence from treatment effects.
  • TLX-101 (Iodine-131 labeled): Phase 3 "IPAX-BRIGHT" trial for recurrent glioblastoma; Phase 2 "IPAX-2" trial for upfront treatment combined with chemoradiation.
• Renal Oncology (Kidney Cancer):
  • Zircax (Zirconium-89): Anti-CA9 PET agent for diagnosis and staging of Clear Cell Renal Cell Carcinoma (CCRCC); Phase 3 "Zircon" trial validated CA9 as a target.
  • Luteon (Lutetium-177 Giratoximab): Phase 3 therapeutic trial targeting CA9 in treatment-refractory metastatic CCRCC; investigating monthly vs. bi-monthly dosing.
• Manufacturing & Supply Chain:
  • Global network of 45 manufacturing sites handling radioactivity.
  • ITM11 Acquisition: Provides control over 80% of global Lutetium-177 supply and future Actinium production; adds a scalable isotope business.
  • Regeneron Collaboration: Focuses on developing Alpha therapies (Actinium-222, Lead-212, Astatine-211) leveraging Telex's new Philadelphia facility for alpha-isotope production.

Market and Competitive Landscape:

• The nuclear medicine sector is pivoting from diagnostic-only (5% CAGR) to theranostics/therapeutics, which is the primary growth driver.
• Infrastructure Race: The industry faces a shortage of high-capacity production infrastructure (reactors/cyclotrons); Telex differentiates by owning a fully vertical, end-to-end supply chain, unlike peers who rely on CDMOs.
• Clinical Paradigm Shifts:
  • Gallium-68 PSMA vs. Fluorine-18: Gallium offers higher specificity, lower false positives, and better image quality, with guidelines increasingly favoring it over Fluorine-18.
  • Pre-biopsy Imaging: Telex is leading the shift to using PSMA PET before biopsy to reduce unnecessary invasive procedures and improve patient selection.
• Therapeutic Competition: Novartis (Pluvicto) and others are active, but Telex is positioning itself as the only company with a full portfolio (small molecule, antibody, next-gen isotopes) and integrated logistics to support multiple assets simultaneously.
• Global Expansion: Commercially active in 22 countries with plans for global availability, aiming to define global standards of care rather than focusing solely on the US market.

Risks and Challenges:

• Supply Chain Complexity: The production of radiopharmaceuticals is highly complex ("melting ice cube"); failure in manufacturing or distribution (even a single missed dose) can damage clinical partnerships and commercial viability.
• Regulatory Uncertainty: Biologics and novel isotopes (e.g., Actinium) face steeper regulatory learning curves and longer approval timelines compared to traditional small molecules.
• Market Saturation/Competition: High demand for isotope infrastructure creates a "race" among ~50 companies; reliance on limited global reactor/cyclotron capacity poses a bottleneck for non-integrated players.
• Clinical Trial Execution: Moving trials to early disease states (e.g., Optimal E) requires precise dosing and timing, and outcomes are subject to biological variability.
• Financial Integration: Successfully integrating the ITM11 business and realizing projected synergies ($50M) without operational disruption.

Management Commentary and Tone:

• Confident and Visionary: Management expresses high conviction that the radiopharma space is entering a "boom" phase, though they reject the "gold rush" label in favor of a strategic, patient-outcome-driven approach.
• Differentiation: Strong emphasis on vertical integration (manufacturing + commercial) as a critical competitive moat that small biotechs cannot easily replicate.
• Strategic Shift: Transitioning from a single-product focus to a "global radiopharma powerhouse" model with a diversified portfolio of 100+ pipeline assets.
• Tone: Optimistic about the 2027-2028 inflection point, highlighting the transition to an earnings-growth story and the ability to fund R&D organically.
• Patient-Centric: Repeatedly references the mission to improve patient outcomes globally, not just maximize profitability in wealthy markets.

Analyst Questions and Answers:

• PSMA Imaging Specificity: Clarification provided that Gallium-68 PSMA offers superior specificity compared to Fluorine-18, reducing false positives in bone scans and improving early disease detection.
• Zirconix (CA9) Timeline: FDA approval for Zirconix (diagnostic) anticipated in 2027, followed by the Luteon (therapeutic) trial data.
• Dosing Strategy (TLX-597): Discussion on "dose intensification" (3 doses in 2 weeks) vs. standard dosing; early data suggests deeper responses and better tolerance in high-volume disease due to lower organ toxicity.
• Actinium Supply: Confirmation of new facilities being built in Philadelphia for Actinium-225 production, addressing the supply bottleneck for alpha therapies.
• Pipeline Agnosticism: Management maintains that they are "vector agnostic" (peptides vs. antibodies vs. amino acids), choosing the targeting agent based on pharmacokinetics and therapeutic index rather than preference.
• Commercial Scale: Questions regarding the shift to a larger commercial footprint; management confirmed that as the portfolio grows to six products, the fixed commercial costs are amortized, improving margins.

Other Key Points:

• Key Opinion Leaders (KOLs): The event featured extensive clinical insights from Dr. Munir Ghassani (Nuclear Medicine), Dr. Philip Dundee (Urologic Surgery), Prof. Louise Emmett (Theranostics), and Prof. Andrew Scott (Neuro-oncology).
• Bypass Study Impact: Potential to triple the volume of patients serviced by moving imaging to the pre-biopsy stage, fundamentally changing the diagnostic pathway for prostate cancer.
• Active Surveillance: Emphasis on using PSMA PET to identify patients with clinically insignificant cancer, thereby avoiding unnecessary biopsies and overtreatment.
• Strategic M&A: The ITM11 transaction is described as the cornerstone for securing isotope supply and enabling alpha-therapy development, with no plans to stop acquiring strategic assets.
• Global Standard Setting: The company aims to establish new medical standards for nuclear medicine globally, ensuring patient access in multiple jurisdictions simultaneously.